The CU Anschutz Medical Campus is a nationally recognized leader in the creation of new knowledge and innovative approaches to improving human health. With sponsored research awards totaling more than $400 million annually, CU Anschutz researchers collaborate with partner and affiliate hospitals, clinics and centers to bring research from the bench to the patient’s bedside.
The CU Anschutz tradition of innovation has created several groundbreaking achievements, including the first liver transplant in the world, the first vaccine for shingles, and the first to use human cell cloning to study genetics and cancer.
Discoveries on the Anschutz Medical Campus have led to new medical devices, pharmaceuticals, diagnostic methods, treatment of debilitating conditions and improved quality of life for patients and consumers worldwide. Since 2002, CU Anschutz technology has led to the filing of 1,300 patent applications and the formation of 53 new companies, funded by more than $914 million in venture capital and public and private equity investment and grants.